EPHX2 and metabolic dysfunction-associated steatotic liver disease: sHE catalyzes the conversion of EETs to DHETs, making sEH inhibitors potential treatments for non-alcoholic fatty liver disease (NAFLD) by decreasing lipid peroxidation, inflammation, and fibrosis (37).